IN THE SPECIFICATION

Please amend the paragraph beginning at page 2, line 27, and continuing through page 3, line 10, as follows:

One approach to the treatment and prevention of Alzheimer's disease has been to develop short peptides having some sequence homology to the natural protein sequence believed to be involved in amyloid formation, but also having one or more amino acid that disfavour or destabilize the formation of β-pleated sheet conformations[15]. The peptides prevent the aggregation of β-amyloid, and thereby prevent its cytotoxic effects. This approach has been suggested in Alzheimer's disease and in prion-related disorders [16,17] and has lead to the β-sheet breaking peptides shown below, amongst others:



WO 96/39834 (New York University)
SEQ ID NO: 1



WO 01/34631
Variant of SEQ ID NO: 1

US 6,319,498 (Praecis Pharmaceuticals) proposes β-sheet breaking peptides based on Aβ, and exemplifies amino-terminally biotinylated peptides. US 6,303,567 (Praecis Pharmaceuticals) proposes peptides based on the β-amyloid peptide, but consisting entirely of D-amino acids, as β-sheet breaking peptides.

Please amend the paragraph beginning at page 4, line 4, as follows:

Summary of the invention

It is an object of the invention to provide a β-sheet breaking peptide with improved pharmacological profile.

In a first aspect, the invention provides a compound of general Formula I:



(I)
Variant of SEQ ID NO: 1

wherein:

R^1 is selected from H and optionally substituted C_2-C_6-acyl, preferably acetyl;

R^2, R^3, R^4 and R^5 are independently selected from H and optionally substituted C_1-C_6 -alkyl and wherein at least one among R^2, R^3, R^4 and R^5 is optionally substituted C_1-C_6 -alkyl, preferably methyl;

R^6 is selected from OH and NR^7R^8, wherein R^7 and R^8 are independently H and optionally substituted C_1-C_6-alkyl, preferably NH_2; and salts and tritiated derivatives thereof.

Please amend the paragraph beginning at page 12, line 6, as follows:

General Protocol:

A preferred pathway for preparing pentapeptides according to the general Formula I, wherein R^2, R^3, R^4 and R^5 are defined above is described in Scheme 1.

Scheme 1:



Variant of SEQ ID NO: 1

In a preferred embodiment the peptides of Formula (I) may be synthesized on a solid support using, for example, preferred Rink-Amide resin.

Please amend Scheme 2, starting at page 14, line 1, as follows:

Scheme 2:



Variant of SEQ ID NO: 1

i.:piperidine 20% in DMF

ii: R^1COCl, pyridine

c)



Variant of SEQ ID NO: 1

TFA, 95% in DCM

d)



Variant of SEQ ID NO: 1

Please amend Table 1, starting at page 16, line 6, as follows:

Table 1

Example	Structure
1	 Variant of SEQ ID NO: 1
2	 Variant of SEQ ID NO: 1
3	 Variant of SEQ ID NO: 1
4	 Variant of SEQ ID NO: 1
5	 Variant of SEQ ID NO: 1
6	 Variant of SEQ ID NO: 1

Please amend the paragraph beginning at page 18, line 2, as follows:

Comparative Example 8

The following compound is disclosed in WO 01/34631 (Axonyx Inc.), and is included as a reference compound.

Example 8:



Variant of SEQ ID NO: 1

Page 30 (Abstract), after the last line, beginning on a new page, please insert the attached Sequence Listing.